Business Context and Reporting Period
This Form 8-K Current Report was filed by Matinas Biopharma Holdings, Inc. on February 1, 2021. The filing discloses topline results from the ENHANCE-IT study, a head-to-head comparative trial of the Company's product candidate LYPDISO against Vascepa in adults with hypertriglyceridemia. The Company is a clinical-stage biopharmaceutical company focused on developing lipid-based therapies.
Key Financial Metrics
This filing is a regulatory disclosure regarding clinical trial results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Results
The filing details significant clinical findings from the ENHANCE-IT study involving two populations: Pharmacodynamic (PD, n=94) and Per Protocol (PP, n=82).
- Plasma EPA Levels: LYPDISO demonstrated a statistically significant 46% relative improvement in plasma eicosapentaenoic acid (EPA) concentrations compared to Vascepa in the PD population.
- Triglyceride Reduction:
- In the PD population, LYPDISO reduced triglycerides by 21.9% versus 15.7% for Vascepa (39% relative improvement), which did not achieve statistical significance.
- In the PP population, LYPDISO reduced triglycerides by 20.9% versus 13.8% for Vascepa (51% relative improvement), achieving statistical significance (P=0.04).
- Other Lipid and Inflammatory Markers: In the PP population, LYPDISO showed statistically significant superior reductions in total cholesterol, VLDL-C, and high-sensitivity C-reactive protein (hsCRP) compared to Vascepa. LYPDISO did not raise LDL cholesterol.
- Safety: No serious adverse events were reported in the study.
Guidance, Outlook, and Risks
Outlook and Strategy: The Company intends to initiate a process to identify a partner for a cardiovascular outcomes study, leveraging the biomarker changes observed which may support potential cardiovascular protection. Full data presentation is expected at upcoming scientific congresses and in peer-reviewed journals.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include the ability to obtain additional capital to meet liquidity needs, uncertainties inherent in clinical testing, the timing and cost of regulatory approvals, and the ability to secure partnerships on favorable terms. The Company's product candidates remain in the development stage and are not yet available for sale.
Investor Verification Checklist
- Verify the full statistical analysis of the ENHANCE-IT study when presented at scientific congresses.
- Monitor the Company's progress in identifying a partner for a pivotal Phase 3 cardiovascular outcomes study.
- Review upcoming 10-Q or 10-K filings for updated liquidity positions and capital requirements.
- Confirm the timeline for the submission of full data to peer-reviewed journals.